

HLAVNÍ TÉMA

GENETIKA FRONTOTEMPORÁLNĚJ DEMENCE

14. Josephs KA, Hodges JR, Snowden JS, et al. Neuropathological background of phenotypical variability in frontotemporal dementia. *Acta Neuropathol.* 2011;122(2):137-53.
15. Josephs KA, Petersen RC, Knopman DS, et al. Clinicopathologic analysis of frontotemporal and corticobasal degenerations and PSP. *Neurology.* 2006;66:41-48.
16. Kashyap SN, Boyle NR, Roberson ED. Preclinical Interventions in Mouse Models of Frontotemporal Dementia Due to Progranulin Mutations. *Neurotherapeutics.* 2023;20(1):140-153. doi:10.1007/s13311-023-01348-6.
17. Kertesz A, McMonagle P, Blair M, et al. The evolution and pathology of frontotemporal dementia. *Brain.* 2005;128:1996-2005.
18. Lagier-Tourenne C, Polymenidou M, Hutt KR, et al. Divergent roles of ALS-linked proteins FUS/TLS and TDP-43 intersect in processing long pre-mRNAs. *Nat Neurosci.* 2012;15(11):1488-97.
19. Le Ber I, De Septenville A, Guerreiro R, et al. Homozygous TREM2 mutation in a family with atypical frontotemporal dementia. *Neurobiol Aging.* 2014 Oct;35(10):2419.e23-2419.e25.
20. Mackenzie IR, Neumann M, Bigio EH, et al. Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. *Acta Neuropathol.* 2010;119:1-4.
21. Majounie E, Renton AE, Mok K, et al. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. *Lancet Neurol.* 2012;11(4):323-30.
22. Neary D, Snowden JS, Gustafson L, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. *Neurology.* 1998;51(6):1546-54.
23. Polymenidou M, Lagier-Tourenne C, Hutt KR, et al. Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43. *Nat Neurosci.* 2011;14(4):459-68.
24. Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. *Brain.* 2011;134(Pt 9):2456-77.
25. Rayaprolu S, Mullen B, Baker M, et al. TREM2 in neurodegeneration: evidence for association of the p.R47H variant with frontotemporal dementia and Parkinson's disease. *Mol Neurodegener.* 2013;8:19. Published 2013 Jun 21. doi:10.1186/1750-1326-8-19.
26. Rektorová I. Frontotemporální lobární degenerace – diagnóza z neuro-psychiatrického pomezí. *Neurol. prax.* 2006;7(4):208-211.
27. Rizzu P, Van Swieten JC, Joosse M, et al. High prevalence of mutations in the microtubule-associated protein tau in a population study of frontotemporal dementia in the Netherlands. *Am J Hum Genet.* 1999;64(2):414-21.
28. Sanders J, Schenk V, van Veen P. A family with Pick disease. *Veerhandelingen de Koninklijke Nederlandse Akademie van Wetenschappen.* 1939.
29. Sieben A, Van Langenhove T, Engelborghs S, et al. The genetics and neuropathology of frontotemporal lobar degeneration. *Acta Neuropathol.* 2012;124(3):353-72.
30. Silvaeh S, König T, Wurm R, et al. Comprehensive genetic screening of early-onset dementia patients in an Austrian cohort suggesting new disease-contributing genes. *Hum Genomics.* 2023;17(1):55. Published 2023 Jun 17. doi:10.1186/s40246-023-00499-z.
31. Snowden J, Neary D, Mann D. Frontotemporal lobar degeneration: clinical and pathological relationships. *Acta Neuropathol.* 2007;114:31-38.
32. Snowden JS, Bathgate D, Varma A, et al. Distinct behavioral profiles in frontotemporal dementia and semantic dementia. *J Neurol Neurosurg Psychiatry.* 2001;70:323-332.
33. Snowden JS, Thompson JC, Stopford CL, et al. The clinical diagnosis of early-onset dementias: diagnostic accuracy and clinicopathological relationships. *Brain.* 2011;134(Pt 9):2478-92.
34. Šutovský S, Malík M, Traubner P, Turčáni P. Primárna progresívna afázia – zriedkavá alebo poddiagnostikovaná. *Neurol. prax.* 2007;8(3):170-173.
35. Taskesen E, Mishra A, van der Sluis S, et al. Susceptible genes and disease mechanisms identified in frontotemporal dementia and frontotemporal dementia with Amyotrophic Lateral Sclerosis by DNA-methylation and GWAS. *Sci Rep.* 2017;7(1):8899. Published 2017 Aug 21. doi:10.1038/s41598-017-09320-z.
36. Ticozzi N, Silani V, LeClerc AL, et al. Analysis of FUS gene mutation in familial amyotrophic lateral sclerosis within an Italian cohort. *Neurology.* 2009;73(15):1180-1185. doi:10.1212/WNL.0b013e3181bbff05.
37. Winfree RL, Seto M, Dumitrescu L, et al. TREM2 gene expression associations with Alzheimer's disease neuropathology are region-specific: implications for cortical versus subcortical microglia. *Acta Neuropathol.* 2023;145(6):733-747. doi:10.1007/s00401-023-02564-2.
38. Xie M, Liu YU, Zhao S, et al. TREM2 interacts with TDP-43 and mediates microglial neuroprotection against TDP-43-related neurodegeneration. *Nat Neurosci.* 2022;25(1):26-38. doi:10.1038/s41593-021-00975-6.
39. Xiao X, Li M, Ye Z, et al. FUS gene mutation in amyotrophic lateral sclerosis: A new case report and systematic review. *Amyotroph. Lateral Scler. Frontotemporal Degener.* 2024;25:1-15.

ON-LINE KURZ

Zaostřeno na syndrom Dravetové

OBSAH KURZU

- ▶ **Co víme o syndromu Dravetové u dospělých?** – prof. MUDr. Petr Marusič, Ph.D.
- ▶ **Na co ještě myslet u dětí?** – MUDr. Martin Kudr, Ph.D.
- ▶ **Cesta k diagnóze – dialog s genetikem** – MUDr. Katalin Štěrbová
- ▶ **Cesta k diagnóze – dialog s genetikem** – MUDr. Jana Zárubová
- ▶ **Cesta k diagnóze – dialog s genetikem** – MUDr. Markéta Vlčková, Ph.D.
- ▶ **Mechanismus účinku a protizáchvatová aktivita fenfluraminu** – MUDr. Ondřej Horák, doc. MUDr. Irena Doležalová, Ph.D.

ODBORNÝ GARANT:

doc. MUDr. Irena Doležalová, Ph.D.

POŘADATEL:

Společnost SOLEN, s. r. o.,
ve spolupráci s I. neurologickou klinikou LF MU
a FN u sv. Anny

Registrace
ZDARMA

TERMÍN

květen 2024 až duben 2025

dostupný na
online.solen.cz



ZLATÝ
PARTNER



Inspired by patients.
Driven by science.

